Dr. Biruh Workeneh, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 286
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Texas Medical School at Houston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license NO565 -
Internal Medicine Physician
CA license A91837
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 286
- Services billed
- 758
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 294 | 128 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 66 | 66 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 37 |
| Critical care, first 30-74 minutes | 37 | 17 |
| Hemodialysis procedure with physician evaluation | 34 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prosol (parenteral amino acid 20% no.1) | 54 |
| Clinisol (parenteral amino acid 15% no.5) | 51 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Houston, TX | 34 |
| Furosemide Other prescribers in Houston, TX | 18 |
| Carvedilol Other prescribers in Houston, TX | 18 |
| Pantoprazole Sodium Other prescribers in Houston, TX | 16 |
| Chlorthalidone Other prescribers in Houston, TX | 14 |
| Jardiance (empagliflozin) Other prescribers in Houston, TX | 14 |
| Sevelamer Carbonate Other prescribers in Houston, TX | 12 |
| Atorvastatin Calcium Other prescribers in Houston, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 83 payments worth $42,843 in total to this clinician.
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $35,351 |
|---|---|
| Travere Therapeutics, Inc. | $5,049 |
| Mallinckrodt Hospital Products Inc. | $418 |
| Amgen Inc. | $414 |
| Calliditas Therapeutics US Inc. | $396 |
| Otsuka America Pharmaceutical, Inc. | $330 |
| Btg International Inc. | $255 |
| Novartis Pharmaceuticals Corporation | $213 |
| Compensation for services other than consulting (speaking, faculty) | $26,792 |
|---|---|
| Consulting Fee | $6,520 |
| Travel and Lodging | $5,951 |
| Food and Beverage | $3,580 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Travere Therapeutics, Inc. Feb 11, 2025 | Consulting Fee | $3,600 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Mar 20, 2025 | Consulting Fee | $2,920 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Dec 10, 2025 | Travel and Lodging travel to IOWA CITY, IA · in-kind | $1,387 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 23, 2025 | Travel and Lodging travel to JUPITER, FL · in-kind | $1,079 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 2, 2025 | Travel and Lodging travel to CREVE COEUR, MO · in-kind | $873 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $822 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Dec 10, 2025 | Travel and Lodging travel to IOWA CITY, IA · in-kind | $1,387 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Dec 7, 2025 | Travel and Lodging travel to IOWA CITY, IA · in-kind | $252 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Travel and Lodging travel to JUPITER, FL | $191 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Travel and Lodging travel to JUPITER, FL | $50.00 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Travel and Lodging travel to JUPITER, FL | $49.00 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Travel and Lodging travel to JUPITER, FL | $34.46 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Travel and Lodging travel to JUPITER, FL | $31.55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Travel and Lodging travel to JUPITER, FL | $15.61 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 21, 2025 | Travel and Lodging travel to JUPITER, FL | $8.00 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 15, 2025 | Travel and Lodging travel to MURRAY, UT · in-kind | $172 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Nov 13, 2025 | Travel and Lodging travel to MURRAY, UT · in-kind | $779 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 23, 2025 | Travel and Lodging travel to JUPITER, FL · in-kind | $1,079 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,424 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 4, 2025 | Travel and Lodging travel to CREVE COEUR, MO · in-kind | $185 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 2, 2025 | Travel and Lodging travel to CREVE COEUR, MO · in-kind | $873 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $274 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $822 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Mar 20, 2025 | Consulting Fee | $2,920 |
| Travere Therapeutics, Inc. Feb 11, 2025 | Consulting Fee | $3,600 |
| Travere Therapeutics, Inc. Feb 11, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $60.00 |
| Travere Therapeutics, Inc. Jan 18, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Dallas, TX · in-kind | $480 |
| Travere Therapeutics, Inc. Jan 18, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Dallas, TX · in-kind | $304 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $393,300 in research payments for these studies, mostly to the institutions running them.
- Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE
Genentech, Inc. - Phase 2b Open-Label Repeat Kidney Biopsy Study
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT06740526 - Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646 - Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
Sanofi US Services Inc. · Active, not recruiting · NCT05039840 - PoCP study in FSGS
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
Novartis Pharmaceuticals Corporation - An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.